glp 1 drugs and menopause GLP-1 weight-loss could cause bone loss GLP-1 weight loss drugs could

1 Introduction The advent of incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their combinations, as pharmacological treatments for obesity and type 2 diabetes, has sparked intense debate about their role relative to traditional lifestyle interventions such as exercise and dietary modification

Promotes weight loss by mimicking a GLP-1 hormone

Can be incorporated into professional cosmetic protocols

Injection site irritation Mild water retention Headache Flushing Temporary changes in appetite Strength : 1mg/0.5mg/ml 6ml vial (1-month supply) Application : Inject as prescribed by your healthcare provider [How to Inject] Dosing : Adjusted to individual medical needs Monitoring : Prescriber consultation required